Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up

Abstract

Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.